FDA Approves ACETAZOLAMIDE — Mylan Institutional LLC

# FDA Approves Mylan Institutional's Intravenous Acetazolamide Sodium Formulation Mylan Institutional LLC received FDA approval for its intravenous acetazolamide sodium formulation (ANDA 200880), expanding the company's presence in the acute diuretic and glaucoma treatment markets and potentially offering hospitals an additional therapeutic option for managing fluid overload and ocular pressure conditions. The approval of the generic intravenous formulation is expected to provide cost-effective alternatives to existing treatments in hospital and clinical settings where IV administration is required.